Glioblastoma multiforme |
GRK3 |
Down |
Increased growth of two different GBM cell lines |
[37] |
GRK5 |
Up |
Positively correlated with aggressiveness of glioma. Increased the proliferation rate of GSC |
[38] |
Medulloblastoma |
GRK6 |
Down |
Enhanced cell migration and CXCL12-mediated phosphorylation of ERK |
[39] |
Thyroid carcinoma |
GRK2 |
Up |
Reduction in proliferation of two poorly differentiated thyroid cell lines |
[41] |
GRK5 |
Down |
Defect in homologous desensitization of the TSH receptor |
[40] |
Breast cancer |
GRK2 |
Up |
Maintenance of tumoral proliferation and survival through regulating HDAC6/Pin1 axis |
[42] |
GRK3 |
Down |
Increase of CXCR4-mediated invasion and metastasis of breast cancer cell |
[47] |
GRK4 |
Up |
Enhanced cell proliferation by activation of ERK and JNK through β-arrestin |
[48] |
Ovarian neoplasm |
GRK2, GRK4 γ/δ |
Up |
Elevated in granulosa cell tumors |
[49] |
Prostate cancer |
GRK2 |
Down |
Trigger androgen-independent tumor growth |
[51] |
GRK3 |
Up |
Increased angiogenesis, prostate tumor growth and metastasis |
[52, 53] |
GRK5 |
Up |
Increased proliferation, invasion, and metastasis of prostate cancer |
[17, 54, 55] |
Colorectal cancer |
GRK5 |
Down |
Increased proliferation regulated by TIG1 |
[57] |
Hepatocellular carcinoma |
GRK2 |
Down |
Increased cell proliferation, migration and invasion |
[58–61] |
Pancreatic cancer |
GRK2 |
Up |
Accelerated cell growth. Predictive for poor overall survival of pancreatic cancer |
[62, 63] |
Lung cancer |
GRK6 |
Down |
Promoted tumor angiogenesis by upregulating MMP-2, MMP-9 release. Decreased survival |
[64, 65] |
Oral squamous cell carcinoma |
GRK3 |
Up |
Tumor malignancy and invasion |
[67] |
Multiple myeloma |
GRK6 |
Up |
Increased survival by enhanced phosphorylation of STAT3 |
[68] |
Kaposi’s sarcoma |
GRK2 |
Down |
Enhanced migration and invasion of endothelial cells via activation of CXCR2/Akt |
[69] |
Osteosarcoma |
GRK5 |
Up |
Decreased apoptosis by phosphorylating p53 and promoting its degradation |
[71] |